The yanking from the market of both Vioxx and Bextra, members of a new generation of pain relievers called COX-2 inhibitors, has critics ripping raw flesh off the Food and Drug Administration. Inevitably, the agency and pharmaceutical companies are under
The Crescent News is available to our paid subscribers.
sign out Welcome,
(edit)